# Cirrhosis Complications: Ascites, SBP, and Hepatorenal Syndrome
## Overview of Decompensated Cirrhosis
Cirrhosis transitions from compensated to decompensated with the development of ascites, variceal bleeding, hepatic encephalopathy, or jaundice. Decompensation carries a median survival of 2 to 4 years compared to more than 12 years in the compensated state. Portal hypertension, defined by a hepatic venous pressure gradient exceeding 10 mmHg, drives most complications. The underlying pathophysiology involves splanchnic vasodilation leading to decreased effective arterial blood volume, which triggers activation of the renin-angiotensin-aldosterone system and the sympathetic nervous system, resulting in sodium and water retention.
## Ascites
### Pathophysiology
Ascites in cirrhosis results from the combination of portal hypertension, splanchnic vasodilation, and renal sodium retention. The underfill theory explains that decreased effective arterial blood volume triggers neurohormonal activation involving RAAS, ADH, and the sympathetic nervous system. Overflow mechanisms contribute additionally as disease progresses.
### Diagnostic Paracentesis
Diagnostic paracentesis should be performed on all patients with new-onset ascites and all hospitalized cirrhotics with ascites, even if asymptomatic. The procedure is safe even with elevated INR or low platelets because the coagulopathy of cirrhosis is "rebalanced," and routine correction is not needed; bleeding complications occur in less than 1% even with INR above 2 or platelets below 50,000. Essential tests include cell count with differential, albumin, and total protein. Additional tests ordered based on clinical indication include culture (with bedside inoculation into blood culture bottles), glucose, LDH, amylase, cytology, and bilirubin if biliary leak is suspected.
### Serum-Ascites Albumin Gradient (SAAG)
The SAAG is calculated by subtracting ascites albumin from serum albumin. A SAAG of 1.1 g/dL or greater indicates portal hypertension with 97% accuracy and is seen in cirrhosis, heart failure, Budd-Chiari syndrome, portal vein thrombosis, and myxedema. A SAAG below 1.1 g/dL indicates non-portal hypertensive causes such as peritoneal carcinomatosis, tuberculous peritonitis, pancreatitis, nephrotic syndrome, and serositis.
### Ascites Fluid Total Protein
| SAAG | Ascites Total Protein | Likely Diagnosis |
|------|---------------------|-----------------|
| ≥1.1 g/dL | <2.5 g/dL | Cirrhosis |
| ≥1.1 g/dL | >2.5 g/dL | Cardiac ascites, Budd-Chiari |
| <1.1 g/dL | >2.5 g/dL | Peritoneal carcinomatosis, TB peritonitis |
| <1.1 g/dL | <2.5 g/dL | Nephrotic syndrome |
Total protein is used alongside SAAG to further narrow the differential. A SAAG of 1.1 or greater with low protein (below 2.5 g/dL) suggests cirrhosis. A SAAG of 1.1 or greater with high protein (above 2.5 g/dL) points to cardiac ascites or Budd-Chiari syndrome. A SAAG below 1.1 with high protein suggests malignancy or tuberculosis.
### Management of Ascites
#### First-Line: Sodium Restriction and Diuretics
Sodium restriction to 2 g per day (88 mEq/day) is the initial step; more restrictive diets are poorly tolerated. Fluid restriction is employed only if serum sodium falls below 125 mEq/L and is not routinely recommended. Diuretic therapy combines spironolactone 100 mg with furosemide 40 mg daily, maintaining the 100:40 ratio to preserve potassium balance. Doses are titrated every 3 to 5 days up to maximum spironolactone 400 mg plus furosemide 160 mg. Target weight loss is 0.5 kg per day without edema and 1 kg per day with edema. Electrolytes and creatinine must be monitored closely, and diuretics should be held if sodium falls below 120, if there is progressive AKI, severe encephalopathy, or severe muscle cramps.
#### Large-Volume Paracentesis (LVP)
Large-volume paracentesis is indicated for tense ascites causing respiratory compromise or for refractory ascites. More than 5 liters can be safely removed per session. Albumin replacement at 6-8 g per liter removed is administered when more than 5 liters are drained, reducing post-paracentesis circulatory dysfunction, hyponatremia, and mortality. For example, removing 8 liters requires approximately 48-64 g of albumin (roughly 2-3 bottles of 25% albumin).
#### Refractory Ascites
Refractory ascites is defined as ascites that does not respond to maximum diuretics plus sodium restriction, or when diuretic-induced complications prevent adequate dosing. Management options include serial large-volume paracentesis with albumin (the most common approach), TIPS (effective for refractory ascites by reducing portal pressure but contraindicated if MELD exceeds 18, in severe encephalopathy, or advanced heart failure), and liver transplant as the definitive treatment (all patients with refractory ascites should be referred). Peritoneovenous shunts are rarely used due to complications including DIC and shunt occlusion.
## Spontaneous Bacterial Peritonitis (SBP)
### Pathophysiology
SBP results from translocation of gut bacteria to mesenteric lymph nodes and ascitic fluid, facilitated by impaired opsonization in low-protein ascites (total protein below 1.5 g/dL). The most common organisms are E. coli, Klebsiella, and Streptococcus pneumoniae, with monomicrobial gram-negatives predominating.
### Diagnosis
An ascitic fluid PMN count of 250 cells/mm3 or greater is diagnostic of SBP, and treatment should begin immediately without waiting for culture results. Culture is positive in only 40-60% of cases; bedside inoculation into blood culture bottles doubles sensitivity. Classic SBP is diagnosed when PMN is 250 or greater with a positive culture. Culture-negative neutrocytic ascites (PMN 250 or greater with negative culture) is treated as SBP. Monomicrobial bacterascites (PMN below 250 with positive culture) warrants repeat paracentesis and treatment if the patient is symptomatic.
### Distinguishing SBP from Secondary Bacterial Peritonitis
Secondary peritonitis is suggested by a surgical abdomen, polymicrobial culture, and two of three findings: glucose below 50, protein above 1, or LDH above the upper limit of normal for serum. It requires imaging (CT) and surgical consultation. Failure to respond to antibiotics within 48 hours should raise suspicion for secondary peritonitis.
### Treatment of SBP
First-line therapy is IV cefotaxime 2 g every 8 hours for 5 days, with IV ceftriaxone 2 g daily as an alternative. IV albumin administered at 1.5 g/kg on day 1 and 1 g/kg on day 3 reduces renal failure and mortality. The Sort et al. trial (NEJM 1999) demonstrated that albumin plus antibiotics reduced mortality from 29% to 10%, with the greatest benefit in patients with bilirubin above 4 or creatinine above 1. Alternative antibiotics include fluoroquinolones (if not on fluoroquinolone prophylaxis) and carbapenems if nosocomial or resistant organisms are suspected. Repeat paracentesis at 48 hours is indicated if there is no clinical improvement, with a greater than 25% decrease in PMN expected.
### SBP Prophylaxis
Primary prophylaxis is indicated when ascites fluid protein is below 1.5 g/dL with renal impairment (creatinine above 1.2) or liver failure (MELD 15 or higher, bilirubin 3 or higher), using norfloxacin 400 mg daily or TMP-SMX DS daily. During GI bleeding, all cirrhotics should receive ceftriaxone 1 g IV daily for 7 days followed by transition to oral fluoroquinolone. Secondary prophylaxis with norfloxacin 400 mg daily or TMP-SMX DS daily is lifelong after the first episode of SBP, continuing until transplant or death. Without prophylaxis, the recurrence rate is approximately 70% at one year.
## Hepatorenal Syndrome (HRS)
### Pathophysiology
Extreme splanchnic vasodilation in advanced cirrhosis leads to severe renal vasoconstriction, producing functional renal failure in the setting of structurally normal kidneys. HRS is defined by the exclusion of other causes of AKI.
### Updated Classification (ICA 2015)
HRS-AKI (formerly Type 1) represents rapidly progressive AKI with creatinine rising more than 0.3 mg/dL within 48 hours or more than 50% from baseline within 7 days. Common precipitants include SBP, GI bleeding, infection, over-diuresis, and large-volume paracentesis without albumin replacement. Median survival without treatment is 2 to 4 weeks. HRS-CKD (formerly Type 2) involves gradual decline in renal function associated with refractory ascites and follows a more indolent course.
### Diagnostic Criteria for HRS-AKI
Diagnosis requires cirrhosis with ascites, AKI per KDIGO criteria, no improvement after 48 hours of diuretic withdrawal and albumin volume expansion (1 g/kg/day for 2 days, maximum 100 g/day), absence of shock, no current or recent nephrotoxic drugs, and no structural kidney disease (no proteinuria above 500 mg/day, no hematuria, normal renal ultrasound).
### Management
Volume expansion with albumin at 1 g/kg/day for 2 days serves as both a diagnostic and therapeutic trial. Vasoconstrictors are used to counteract splanchnic vasodilation. Terlipressin, a V1 receptor agonist FDA-approved in 2022 for HRS-AKI based on the CONFIRM trial, is dosed at 0.5-1 mg IV every 6 hours and titrated to a maximum of 2 mg every 6 hours. It achieves HRS-AKI reversal in approximately 30% of patients versus 15% with placebo, but carries safety concerns including respiratory failure (especially in ACLF grade 3) and ischemic events; it should be avoided if SpO2 is below 90%. Norepinephrine infusion titrated to achieve a MAP increase of 10 mmHg is a cheaper ICU alternative. Midodrine (7.5-12.5 mg three times daily) plus octreotide (100-200 mcg three times daily subcutaneously) plus albumin (25-50 g/day) is less effective but commonly used when terlipressin or norepinephrine is unavailable. TIPS may improve renal function in selected patients but is contraindicated in severe liver failure. Liver transplant is the only definitive treatment, with simultaneous liver-kidney transplant considered if renal replacement therapy has been required for more than 6 weeks. Renal replacement therapy serves as a bridge to transplant and is not beneficial without transplant candidacy.
## Albumin Use in Cirrhosis -- Summary
Albumin has strong evidence supporting its use in SBP treatment (1.5 g/kg day 1, 1 g/kg day 3 with mortality benefit), after large-volume paracentesis exceeding 5 liters (6-8 g per liter removed), and as a diagnostic challenge in HRS-AKI (1 g/kg/day for 2 days, maximum 100 g/day). Weekly albumin infusion remains debated: the ANSWER trial supported 40 g twice weekly, but the ATTIRE trial was negative for hospitalized patients.
A diagnostic algorithm for ascites evaluation. Start with "New Ascites or Hospitalized Cirrhotic" leading to diagnostic paracentesis. Branch based on SAAG: >=1.1 (portal hypertension) vs. <1.1 (non-portal hypertension). Within SAAG >=1.1, further differentiate by ascites total protein: <2.5 (cirrhosis) vs. >2.5 (cardiac, Budd-Chiari). Show the SBP diagnostic pathway: PMN >=250 triggers immediate treatment. Include SAAG calculation formula and interpretation rules.
A stepwise management flowchart for hepatorenal syndrome. Begin with "AKI in Cirrhotic with Ascites," proceed through: hold diuretics and nephrotoxins, albumin challenge (1 g/kg x 2 days), reassess at 48 hours. If no improvement: diagnose HRS-AKI. Show treatment options: terlipressin + albumin (first-line where available), norepinephrine + albumin (ICU alternative), midodrine + octreotide + albumin (ward alternative). End with liver transplant as definitive therapy. Include the CONFIRM trial result sidebar.
An infographic summarizing albumin use in cirrhosis across four clinical scenarios: SBP (1.5 g/kg day 1, 1 g/kg day 3 -- mortality benefit), large-volume paracentesis (6-8 g/L removed), HRS-AKI (diagnostic challenge dose), and long-term weekly infusion (ANSWER vs. ATTIRE trial results). Use green checkmarks for strong evidence and yellow question marks for debated indications.
## Clinical Pearls
Diagnostic paracentesis should be performed on every hospitalized cirrhotic with ascites because SBP is present in up to 15% and is often asymptomatic. Coagulopathy should not be corrected before paracentesis because the rebalanced hemostasis of cirrhosis means INR does not predict bleeding risk, and routine FFP or platelet transfusion is unnecessary. A SAAG of 1.1 or greater means portal hypertension with 97% accuracy, making it the single most important test in ascites evaluation. SBP should be treated immediately when PMN reaches 250 cells/mm3 or higher without waiting for cultures, and albumin co-administration reduces mortality from 29% to 10%. After a first episode of SBP, lifelong antibiotic prophylaxis must be started because without it, 70% of patients recur within one year. The albumin challenge (1 g/kg for 2 days) is both diagnostic and therapeutic in suspected HRS-AKI and should always be tried before escalating to vasoconstrictors. Terlipressin is effective for HRS-AKI but carries serious risks including respiratory failure, and it should be avoided in patients with ACLF grade 3 or baseline hypoxemia. All patients with decompensated cirrhosis should be referred for transplant evaluation without waiting until they are too sick.
## References
- Runyon BA. AASLD Practice Guideline: Management of Adult Patients with Ascites Due to Cirrhosis. Hepatology. 2013 (updated 2021).
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Decompensated Cirrhosis. J Hepatol. 2018.
- Sort P, et al. Effect of IV Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and SBP. NEJM. 1999.
- Wong F, et al. CONFIRM Trial: Terlipressin Plus Albumin for HRS-AKI. NEJM. 2021.
- Caraceni P, et al. ANSWER Trial: Long-Term Albumin Administration in Decompensated Cirrhosis. Lancet. 2018.
- China L, et al. ATTIRE Trial: Albumin in Hospitalized Patients with Cirrhosis. NEJM. 2021.
- Angeli P, et al. ICA Consensus: Diagnosis and Management of AKI in Cirrhosis. J Hepatol. 2015.
- Biggins SW, et al. AASLD Practice Guidance: Diagnosis, Evaluation, and Management of Ascites, SBP, and HRS. Hepatology. 2021.